Ekso Bionics stock plunges to 52-week low at $0.25

Published 20/05/2025, 14:42
Ekso Bionics stock plunges to 52-week low at $0.25

Ekso Bionics Holdings Inc. (EKSO) stock has tumbled to a 52-week low, reaching a price level of just $0.25. According to InvestingPro data, the company’s market capitalization has shrunk to $7.4 million, with the stock currently trading at 0.76 times book value. This significant drop reflects a challenging year for the company, with the stock experiencing a precipitous decline of -74.92% over the past year. Investors have been closely monitoring the company’s performance, as the current price marks the lowest point for the stock within the last year, raising concerns about the company’s future prospects and the potential for a turnaround. InvestingPro analysis indicates the stock is currently undervalued, with additional metrics and 13 more ProTips available to subscribers, including detailed insights on the company’s cash position and financial health score of 2.22 (FAIR).

In other recent news, Ekso Bionics reported a larger-than-expected loss for the first quarter of 2025, with earnings per share at -$0.12, missing the analyst forecast of -$0.08. The company’s revenue for the quarter was $3.4 million, which fell short of the anticipated $4.8 million. This revenue decline is partly due to decreased enterprise sales of the EksoNR, though there was an increase in sales of the Ekso Indego Personal. H.C. Wainwright adjusted its price target for Ekso Bionics shares from $9.00 to $4.00, maintaining a Buy rating, citing a decline in enterprise revenue due to customer budget cuts. Ekso Bionics has also announced a 1-for-15 reverse stock split to comply with the Nasdaq Capital Market’s minimum bid price requirement. The reverse stock split, approved by shareholders, aims to stabilize the company’s market position by reducing the number of outstanding shares. Despite the downturn in revenue, the company maintains a gross margin of 54% and reported a gross profit of $1.8 million. Ekso Bionics anticipates a recovery in enterprise sales from integrated delivery networks later this year, contingent on improvements in the broader macroeconomic climate.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.